Lung Cancer Reagents | abinScience

Lung cancer remains the leading cause of cancer-related mortality worldwide, with NSCLC accounting for ~85% of all cases. abinScience provides a comprehensive portfolio of antibodies, recombinant proteins, and ELISA kits covering EGFR, ALK, KRAS, PD-L1, VEGF, and other key oncogenic drivers and immune checkpoints critical to lung cancer research and drug development. RUO

Key Biomarkers & Targets

EGFR

ErbB1 / HER1

Mutated in ~15–30% of NSCLC; primary target for TKIs (gefitinib, osimertinib). 150+ antibodies and biosimilar-grade proteins available.

Antibodies • Proteins • Biosimilars

ALK

Anaplastic Lymphoma Kinase

ALK rearrangements drive ~5% of NSCLC. Reagents for fusion protein detection and crizotinib/alectinib mechanism studies. 110+ products.

Antibodies • Biosimilars

PD-L1 / PD-1

CD274 / CD279

Central to immune checkpoint blockade in NSCLC. PD-L1 expression (IHC TPS) guides first-line pembrolizumab eligibility. 260+ reagents across both targets.

Antibodies • Proteins • Biosimilars

KRAS

K-Ras4B

KRAS G12C mutation present in ~13% of NSCLC — the first "undruggable" oncogene to yield approved therapies (sotorasib, adagrasib).

Antibodies

VEGF / VEGFR

Vascular Endothelial Growth Factor

Key angiogenesis axis; bevacizumab backbone of NSCLC combination regimens. 160+ antibodies and recombinant proteins.

Antibodies • Proteins • Biosimilars

CEA

CEACAM5 / CD66e

Serum biomarker for adenocarcinoma subtype monitoring. Also emerging bispecific antibody target (cibisatamab). 80+ products.

Antibodies • Biosimilars

Why Researchers Choose abinScience for Lung Cancer

Driver Mutation Coverage Reagents targeting all major NSCLC actionable mutations — EGFR, ALK, ROS1, RET, NTRK, BRAF, MET, KRAS G12C — for comprehensive molecular profiling.

Checkpoint Immunotherapy Panel PD-1, PD-L1, CTLA-4, TIGIT, LAG-3, TIM-3 — supporting companion diagnostic development and immune response characterization.

Biosimilar-Grade Reference Proteins Research-grade biosimilars of approved NSCLC therapeutics for binding assays, cell-based potency tests, and pharmacokinetic studies.

Protein–Antibody–Kit Workflow Same target available as recombinant protein, detection antibody, and ELISA kit — streamline your assay development with one supplier.

Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

Molecular subtyping: EGFR/ALK/ROS1/KRAS mutation status drives NSCLC treatment selection. Use our antibodies (IHC, WB) and proteins (ELISA, SPR) for genotype-phenotype validation.
PD-L1 expression profiling: Quantify PD-L1 on tumor cells and tumor-infiltrating immune cells to stratify immunotherapy response potential.
Anti-angiogenic drug development: VEGF/VEGFR proteins and antibodies for receptor-binding assays, endothelial tube formation studies, and bevacizumab biosimilar comparability.
Liquid biopsy biomarker validation: CEA antibodies (ELISA/IHC validated) for circulating biomarker research in NSCLC monitoring.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which EGFR antibodies detect both wild-type and mutant forms?

We offer anti-EGFR polyclonal antibodies (ELISA, IHC, WB; Human/Mouse/Rat) and monoclonal clones (e.g., 1A112–1A114, IHC/WB validated). Research-grade EGFR biosimilar proteins are also available.

Do you offer ALK fusion-specific reagents?

We offer anti-ALK polyclonal antibodies with ELISA, IHC, and WB validation, monoclonal clones (e.g., SAA0129 with FC; ab324 with FC in FITC/APC/PE/PerCP), and research-grade ALK biosimilar proteins.

What PD-L1 scoring systems do your antibodies support?

Yes — we carry multiple anti-PD-L1 clones: 22C3 and SP142/SP263 (ELISA, IHC, WB; available in FITC/APC/PE/PerCP conjugates), plus clones 1A058–1A064 (ELISA, IHC, WB; unconjugated). Research use only, not companion diagnostics.

Can I get NSCLC-relevant multiplex panels?

We carry IHC-validated antibodies for EGFR, PD-L1 (22C3, SP142), and Ki-67. For targets like TTF-1 and CK7, see product pages for current application data. Contact us for panel assembly guidance.

Do you offer custom antibody development for novel lung cancer targets?

Yes — our parent company AtaGenix provides full custom antibody services from immunogen design through hybridoma production, covering novel NSCLC targets not yet in our catalog.